All In Biotech

Drug Trial Radar · NCT06256588

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 864 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

864

Planned (sponsor's estimate)

Start

Mar 21, 2024

Primary completion

Jun 30, 2028

Study completion Oct 26, 2029

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Conditions

  • Neoplasms, Head and Neck

Interventions

  • DostarlimabDrug

    Dostarlimab will be administered as an intravenous (IV) infusion

  • PlaceboDrug

    Placebo will be administered as an IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 5 years

Locations

277 sites in 31 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Jonesboro, Arkansas · Recruiting

  • GSK Investigational Site

    Los Angeles, California · Recruiting

  • GSK Investigational Site

    Solvang, California · Recruiting

  • GSK Investigational Site

    Stockton, California · Recruiting

  • GSK Investigational Site

    Torrance, California · Recruiting

  • GSK Investigational Site

    Farmington, Connecticut · Recruiting

  • GSK Investigational Site

    New Haven, Connecticut · Recruiting

  • GSK Investigational Site

    Washington D.C., District of Columbia · Recruiting

  • GSK Investigational Site

    St. Petersburg, Florida · Recruiting

  • GSK Investigational Site

    Tamarac, Florida · Withdrawn

  • GSK Investigational Site

    Atlanta, Georgia · Recruiting

  • GSK Investigational Site

    Fort Wayne, Indiana · Recruiting

  • GSK Investigational Site

    Iowa City, Iowa · Recruiting

  • GSK Investigational Site

    Lexington, Kentucky · Recruiting

  • GSK Investigational Site

    Columbia, Maryland · Recruiting

  • GSK Investigational Site

    Worcester, Massachusetts · Recruiting

  • GSK Investigational Site

    St Louis, Missouri · Recruiting

  • GSK Investigational Site

    Omaha, Nebraska · Recruiting

  • GSK Investigational Site

    New York, New York · Completed

  • GSK Investigational Site

    The Bronx, New York · Recruiting

  • GSK Investigational Site

    Canton, Ohio · Recruiting

  • GSK Investigational Site

    Cincinnati, Ohio · Completed

  • GSK Investigational Site

    Tulsa, Oklahoma · Recruiting

  • GSK Investigational Site

    Philadelphia, Pennsylvania · Recruiting

  • GSK Investigational Site

    Pittsburgh, Pennsylvania · Recruiting

  • GSK Investigational Site

    Charleston, South Carolina · Recruiting

  • GSK Investigational Site

    Greenville, South Carolina · Completed

  • GSK Investigational Site

    Chattanooga, Tennessee · Recruiting

  • GSK Investigational Site

    Germantown, Tennessee · Recruiting

  • GSK Investigational Site

    Nashville, Tennessee · Recruiting

  • GSK Investigational Site

    Dallas, Texas · Recruiting

  • GSK Investigational Site

    Fort Worth, Texas · Recruiting

  • GSK Investigational Site

    San Antonio, Texas · Recruiting

  • GSK Investigational Site

    Fredericksburg, Virginia · Recruiting

  • GSK Investigational Site

    Wytheville, Virginia · Recruiting

  • GSK Investigational Site

    Tacoma, Washington · Withdrawn

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, Argentina · Recruiting

Showing 40 of 277 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.